

### REMARKS

The Official Action dated March 29, 2006 has been carefully considered. Accordingly, it is believed that the present Amendment places this application in condition for allowance. Reconsideration is respectfully requested.

By the present Amendment, the title has been amended to more specifically describe the claimed compositions, and the specification and claims 1 and 9-13 have been amended to correct the typographical error of "nagiimide" to "nadimide", to refer to compounds based on nadic anhydride. Claim 1 has also been amended to include limitations from claim 8, claims 6-8 and 14 have been canceled, and claims 15-18 are amended to correspond with claim 1 as amended. It is believed that these changes do not involve any introduction of new matter, whereby entry is believed to be in order and is respectfully requested.

In the Official Action, the Examiner repeated the requirement under 35 U.S.C. §121 to elect a single disclosed species for prosecution on the merits. Applicants affirm the election of the species of Formula (IV). However, Applicants submit that claims 9-18 withdrawn by the Examiner should be examined on the merits as these claims also read on the elected species. Accordingly, examination of all of pending claims 1-5, 9-13 and 15-20 in the present application is respectfully requested.

The Examiner had requested a more descriptive title for the application. It is believed that the title presented herein is clearly descriptive of the claimed subject matter.


Claim 7 was rejected under 35 U.S.C. §112, second paragraph, as being indefinite. The Examiner questioned the term "nagiimide". Although claim 7 has been cancelled, the remaining claims and the specification have been amended to correct the typographical error of "nagiimide" and set forth the correct term "nadimide" to describe the compounds based on nadic anhydride. It is believed that the claims are definite, whereby the rejection under 35 U.S.C. §112, second paragraph, has been overcome.

Finally, claims 1-7, 19 and 20 were rejected under 35 U.S.C. §102(b) as anticipated by or, in the alternative, under 35 U.S.C. §103(a) as obvious over JP 63-205358, and under 35 U.S.C. §103(a) as being unpatentable over JP 63-205358 in view of the Nishihata U.S. Patent Publication 2002/0107335 or EP 950691. The Examiner noted however that claim 8 would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The rejections under 35 U.S.C. §§102 and/or 103 are traversed. However, to expedite prosecution, Applicants have amended claim 1 to include the limitations of claim 8. Moreover, Applicants submit that the bisnadimide compound represented by Formula (IV) set forth in claim 1 inherently includes the limitations of claims 6 and 7 from which claim 8 had depended. Accordingly, claim 1 corresponds with claim 8 rewritten in independent form. Applicants therefore submit that claim 1 and claims 2-5, 9-13 and 15-20 depending directly or indirectly from claim 1 are in prima facie condition for allowance. Reconsideration is respectfully requested.

It is believed that the above represents a complete response to the Official Action, and places the present application in condition for allowance. Reconsideration and an early allowance are requested.

Respectfully submitted,



Holly D. Kozlowski, Reg. No. 30,468  
DINSMORE & SHOHL LLP  
1900 Chemed Center  
255 E. Fifth Street  
Cincinnati, Ohio 45202  
(513) 977-8568